



Express Mail Mailing Label No. EV334240785US

SHEET 1 OF 3

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>					
				SERIAL NO.: 09/256,156					
				FILING DATE: February 24, 1999 GROUP: 1647					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
RKH	A95	5,601,819	2/11/97	Wong et al.					
	A96	5,624,821	4/29/97	Winter et al.					
	A97	5,679,543	10/21/97	Lawlis					
	A98	5,891,680	4/6/99	Lieschke et al.					
	A99	5,994,104	11/30/99	Anderson et al.					
	A100	6,429,199	8/6/02	Krieg et al.					
	A101	6,551,592	4/22/03	Lindhofer et al.					
	A102	6,646,113	11/11/03	Dreyfuss et al.					
	A103	2002/0037558	3/28/02	Lo et al.					
	A104	2002/0146388	10/10/02	Gillies					
	A105	2003/0139365	7/24/03	Lo et al.					
	A106	2003/0139575	7/24/03	Gillies					
	A107	2004/0033210	2/19/04	Gillies					
	A108	2004/0053366	3/18/04	Lo et al.					
	A109	2004/0072299	4/15/04	Gillies et al.					
RKH	A110	2004/0082039	4/29/04	Gillies et al.					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
RKH	B106	WO 93/20185	10/14/93	PCT					
RKH	B107	WO 97/43316	11/20/97	PCT					
EXAMINER <i>Ronald K. Hunsicker</i>				DATE CONSIDERED <i>9/7/04</i>					



FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-003	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>	
		SERIAL NO.: 09/256,156	
		FILING DATE: February 24, 1999 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
RKH	C236	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386.	
	C237	Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204.	
	C238	Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , p.158, CRC Press, NY.	
	C239	de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co.	
	C240	Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217.	
	C241	Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491.	
	C242	Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713.	
	C243	Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071.	
	C244	Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267.	
	C245	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105.	
	C246	Harvill et al., (1996), "In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation," <u>J. Immunology</u> , 157(7):3165-3170.	
	C247	Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142.	
	C248	Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729.	
	C249	Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128.	
RKH	C250	Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696.	
EXAMINER	RKH		DATE CONSIDERED 9/7/04



PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

EXAM.
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

RKH	C251	Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386
	C252	Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705.
	C253	Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349.
	C254	Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212
	C255	Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antibod. Hybridomas</u> , 3:19-24.
	C256	Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <u>J. Exp. Med.</u> , 179:1109-1118.
	C257	Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133.
	C258	Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846.
RKH	C259	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474.

EXAMINER

David K. Himmelfarb

DATE CONSIDERED

9/7/04

FORM PTO - 1449


SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647



U.S. PATENT DOCUMENTS

EXAM & TRADEMARK INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	A55	4,703,008	10/27/87	Lin			
/	A56	5,019,368	5/28/91	Epstein <i>et al.</i>			
/	A57	5,441,868	8/15/95	Lin			
/	A58	5,457,038	10/10/95	Trinchieri <i>et al.</i>			
/	A59	5,547,933	8/20/96	Lin			
/	A60	5,618,698	4/8/97	Lin			
/	A61	5,645,835	7/8/97	Fell, Jr. <i>et al.</i>			
/	A62	5,688,679	11/18/97	Powell			
/	A63	5,756,349	5/26/98	Lin			
/	A64	5,807,715	9/15/98	Morrison <i>et al.</i>			
/	A65	5,856,298	1/5/99	Strickland			
/	A66	5,888,772	3/30/99	Okasinski <i>et al.</i>			
/	A67	5,922,685	7/13/99	Rakhmievich <i>et al.</i>			
/	A68	5,955,422	9/21/99	Lin			
/	A69	6,231,536	5/15/01	Lentz			
/	A70	6,284,536	9/4/01	Morrison <i>et al.</i>			
/	A71	6,335,176	1/1/02	Inglese <i>et al.</i>			
/	A72	6,340,742	1/22/02	Burg <i>et al.</i>			
/	A73	6,348,192	2/19/02	Chan <i>et al.</i>			
/	A74	6,444,792	9/3/02	Gray <i>et al.</i>			
/	A75	6,475,717	11/5/02	Ensle <i>et al.</i>			
/	A76	6,485,726	11/26/02	Blumberg <i>et al.</i>			
/	A77	6,506,405	1/14/03	Desai <i>et al.</i>			
/	A78	6,583,272	6/24/03	Bailon			
/	A79	6,586,398	7/1/03	Kinstler <i>et al.</i>			
RKH	A80	6,617,135	9/9/03	Gillies <i>et al.</i>			
EXAMINER	Ramon K. Hummelt			DATE CONSIDERED	9/7/04		

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	A81	2001/0053539	12/20/01	Lauffer et al.			
/	A82	2002/0081664	6/27/02	Lo et al.			
/	A83	2002/0142374	10/3/02	Gallo et al.			
/	A84	2002/0147311	10/10/02	Gillies et al.			
/	A85	2002/0192222	12/19/02	Blumberg et al.			
/	A86	2002/0193570	12/19/02	Gillies et al.			
/	A87	2003/0003529	1/2/03	Bayer			
/	A88	2003/0044423	3/6/03	Gillies et al.			
/	A89	2003/0049227	3/13/03	Gillies et al.			
/	A90	2003/0105294	6/5/03	Gillies et al.			
/	A91	2003/0012789	1/6/03	Blumberg et al.			
/	A92	2003/0157054	8/21/03	Gillies et al.			
/	A93	2003/0166163	9/4/03	Gillies			
RKH	A94	2003/0166877	9/4/03	Gillies et al.			

FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
RKH	B83	0 318 554 B1	6/7/89	EP					Y
/	B84	0 640 619 A1	3/1/95	EP					Y
/	B85	0 668 353 A1	8/23/95	EP					Y
/	B86	1 088 888 A1	4/4/01	EP					Y
/	B87	WO 94/24160	10/27/94	PCT					Y
/	B88	WO 94/25055	11/10/94	PCT					Y
/	B89	WO 99/60128	11/25/99	PCT					Y
/	B90	WO 99/66054	12/23/99	PCT					Y
RKH	B91	WO 00/24893	5/4/00	PCT					

EXAMINER

David K. Himmelfarb

DATE CONSIDERED

9/7/04

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647


U.S. PATENT DOCUMENTS


EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	B92	WO 00/68376	11/16/00	PCT			Y
	B93	WO 00/78334	12/28/00	PCT			Y
	B94	WO 01/10912	2/15/01	PCT			Y
	B95	WO 01/36489	5/25/01	PCT			Y
	B96	WO 01/58957	8/16/01	PCT			
	B97	WO 02/02143	1/10/02	PCT			
	B98	WO 02/066514	8/29/02	PCT			Y
	B99	WO 02/072605	9/19/02	PCT			
	B100	WO 02/079232	10/10/02	PCT			
	B101	WO 02/079415	10/10/02	PCT			
	B102	WO 02/090566	11/14/02	PCT			
	B103	WO 03/015697	2/27/03	PCT			Y
	B104	WO 03/048334	6/12/03	PCT			
RKH	B105	WO 03/077834	9/25/03	PCT			Y

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)						
RKH	C143	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.					
	C144	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108.					
	C145	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.					
	C146	Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J Clin Invest.</u> , 98(12):2801-2804.					
	C147	Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J Exp. Med.</u> , 183(50):2361-6.					
RKH	C148	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193.					

EXAMINER	<i>David R. Hummel</i>	DATE CONSIDERED	<i>9/7/04</i>
----------	------------------------	-----------------	---------------

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>			
				SERIAL NO.: 09/256,156			
				FILING DATE: February 24, 1999 GROUP: 1647			
PATENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
RKH	C149		Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.				
/	C150		Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993.				
/	C151		Briggs et al., (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388.				
/	C152		Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415.				
/	C153		Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587.				
/	C154		Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355.				
/	C155		Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.				
/	C156		Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.				
/	C157		Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713.				
/	C158		Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.				
/	C159		Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.				
/	C160		Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.				
/	C161		Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7.				
/	C162		Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.				
/	C163		Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13.				
/	C164		Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.				
RKH	C165		Fell et al., (1992), "Chimeric L6 Antitumor Antibody," <u>J. Biol. Chem.</u> , 267(122):15552-15558.				
EXAMINER <i>Ronald K. Hummelt</i>				DATE CONSIDERED <i>9/7/04</i>			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>			
				SERIAL NO.: 09/256,156			
				FILING DATE: February 24, 1999 GROUP: 1647			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH		C166		Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236.			
	/	C167		Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33.			
	/	C168		Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42.			
	/	C169		Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.			
	/	C170		Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.			
	/	C171		Gillies et al., (2002), "Improved Circulating Half-life and eRfficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.			
	/	C172		Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.			
	/	C173		Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782.			
	/	C174		Hammerling et al. (1996), "In Vitro Bioassay for Human Erythropoietin based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.			
	/	C175		Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9.			
	/	C176		Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31.			
	/	C177		Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.			
	/	C178		Harris, (1995), "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture," <u>J. Chromatogr. A</u> , 705:129-134.			
	/	C179		Hezareh et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8.			
	/	C180		Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.			
RKH		C181		Hu et al., (1996), "A Chimeric Lym-I/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.			
EXAMINER <i>Ramul K. Hummelt</i>				DATE CONSIDERED <i>9/7/04</i>			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>			
				SERIAL NO.: 09/256,156			
				FILING DATE: February 24, 1999 GROUP: 1647			
							
PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	/	C182		Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <i>J. Immunol.</i> , 164(8):4178-4184.			
	/	C183		Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <i>Cancer Res.</i> , 61(4):1500-7.			
	/	C184		Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <i>Journal of Biological Chemistry</i> , 262(12):5723-5731.			
	/	C185		Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 283:520-527.			
	/	C186		Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <i>Drug Metabolism and Disposition</i> , 26:126-131.			
	/	C187		Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <i>Journal of Cellular Physiology</i> , 140:323-334.			
	/	C188		Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <i>J. Clin. Oncol.</i> , 19:4189-94.			
	/	C189		Locatelli et al., (2001), "Darbepoetin alfa Amgen," <i>Current Opinion in Investigational Drugs</i> , 2:1097-1104.			
	/	C190		Lode et al., (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <i>J Natl Cancer Inst.</i> , 89(21):1586-94.			
	/	C191		Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <i>Pharmacol. Ther.</i> , 80(3):277-292.			
	/	C192		Lode et al., (2000), "What to do with Targeted IL-2," <i>Drugs Today</i> , 36(5):321-36.			
	/	C193		Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <i>J. Clin. Invest.</i> , 105(11):1623-30.			
	/	C194		Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <i>Nephrol. Dial. Transplant.</i> , 17:66-70.			
	/	C195		Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <i>Blood</i> , 99(11):4166-73.			
	/	C196		Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <i>J. Mol. Biol.</i> , 247:979-994.			
RKH	/	C197		Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <i>Molecular Immunology</i> , 34(6):441-452.			
EXAMINER <i>Rachel K. Hummel</i>				DATE CONSIDERED <i>9/7/04</i>			

FORM PTO - 1449


SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647



PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	C198		Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.			
/	C199		Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492.			
/	C200		Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9.			
/	C201		Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol Immunother.</u> , 53:41-52.			
/	C202		Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458.			
/	C203		Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142.			
/	C204		Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston.			
/	C205		Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9.			
/	C206		Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Murine Melanoma," <u>Cancer Res.</u> , 61(16):6178-84.			
/	C207		Nimt et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.			
/	C208		Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.			
/	C209		Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.			
/	C210		Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040.			
/	C211		Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6.			
RKH	C212		Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12.			
EXAMINER	Daniel K. Hummer			DATE CONSIDERED	9/7/04	

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	/	C213		Roessler et al., (1994), "Cooperative Interactions between the Interleukin 2 Receptor α and β Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347.			
/	/	C214		Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503.			
/	/	C215		Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.			
/	/	C216		Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site of the α -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640.			
/	/	C217		Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214.			
/	/	C218		Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202.			
/	/	C219		Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028.			
/	/	C220		Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.			
/	/	C221		Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.			
/	/	C222		Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456.			
/	/	C223		Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-267 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc.			
/	/	C224		Syed et al., (1998), "Efficiency of Signaling through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516.			
/	/	C225		Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.			
/	/	C226		Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20.			
/	/	C227		Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672.			
RKH	/	C228		Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.			
EXAMINER <i>David K. Hummel</i>				DATE CONSIDERED <i>9/7/04</i>			

FORM PTO - 1449				ATTORNEY DOCKET NO.: LEX-003			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Gillies <i>et al.</i>			
				SERIAL NO.: 09/256,156			
				FILING DATE: February 24, 1999 GROUP: 1647			
U.S. PATENT DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RKH	/	C229		Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516.			
	/	C230		Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.			
	/	C231		Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83.			
	/	C232		Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J Immunol.</u> , 167(8):4560-5.			
	/	C233		Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864.			
	/	C234		Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80.			
RKH	/	C235		Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.			
EXAMINER <i>David K. Himmelfarb</i>				DATE CONSIDERED <i>9/7/04</i>			